Introduction：Basic information about CAS 98048-97-6|Fosinopril, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Fosinopril |
|---|
| CAS Number | 98048-97-6 | Molecular Weight | 563.66300 |
|---|
| Density | 1.173 g/cm3 | Boiling Point | 705.7ºC at 760 mmHg |
|---|
| Molecular Formula | C30H46NO7P | Melting Point | 149-153ºC |
|---|
| MSDS | / | Flash Point | 380.6ºC |
|---|
Names
| Name | fosinopril |
|---|
| Synonym | More Synonyms |
|---|
Fosinopril BiologicalActivity
| Description | Fosinopril (SQ28555) is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value of 0.18 μM[1]. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2]. |
|---|
| Related Catalog | Signaling Pathways >>Apoptosis >>ApoptosisResearch Areas >>Cardiovascular DiseaseSignaling Pathways >>Metabolic Enzyme/Protease >>Angiotensin-converting Enzyme (ACE) |
|---|
| Target | IC50: 0.18 μM; Ki: 1.675 μM |
|---|
| In Vitro | Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2[1]. Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2[1]. Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2]. |
|---|
| In Vivo | Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration[3]. Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model[3]. Animal Model: HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g) [3] Dosage: 4.67 mg/kg Administration: p.o.; 4 weeks Result: Against cardiac dysfunction and structural alteration and suppressed apoptosis. |
|---|
| References | [1]. Ondetti, M.A., Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation, 1988. 77(6 Pt 2): p. I74-8. [2]. Piepho, R.W., Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm, 2000. 57 Suppl 1: p. S3-7. [3]. Sharma, S., et al., The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther, 1999. 6(4): p. 181-9. |
|---|
Chemical & Physical Properties
| Density | 1.173 g/cm3 |
|---|
| Boiling Point | 705.7ºC at 760 mmHg |
|---|
| Melting Point | 149-153ºC |
|---|
| Molecular Formula | C30H46NO7P |
|---|
| Molecular Weight | 563.66300 |
|---|
| Flash Point | 380.6ºC |
|---|
| Exact Mass | 563.30100 |
|---|
| PSA | 120.02000 |
|---|
| LogP | 6.05920 |
|---|
| Index of Refraction | 1.531 |
|---|
| InChIKey | BIDNLKIUORFRQP-AJTMIRJTSA-N |
|---|
| SMILES | CCC(=O)OC(OP(=O)(CCCCc1ccccc1)CC(=O)N1CC(C2CCCCC2)CC1C(=O)O)C(C)C |
|---|
| Water Solubility | Insoluble |
|---|
Safety Information
Customs
Synonyms
| fosenopril |
| Staril |
| Fosinopril |
| MFCD00870759 |
| Secorvas |
